Aerovate’s lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101’s anti-proliferative mechanism is distinguished from current vasodilatory therapies and poised to make a meaningful difference in the lives of PAH patients.

Aerovate Therapeutics Inc

Should you buy, sell, or hold Aerovate Therapeutics Inc (AVTE) ?

Aerovate Therapeutics Inc (AVTE) : Buy or Sell